Intravenous sedation for upper gastrointestinal endoscopy: diazepam versus midazolam
Intravenous diazepam (Valium) has a long half life (>20 hours) and active metabolites and, possibly due to its vehicle, may damage veins; in contrast, midazolam hydrochloride (Hypnovel), a new water soluble imidazobenzodiazepine, has an elimination half life of about two hours. We compared these two drugs as sedatives for elective upper gastrointestinal endoscopy.
Patients, methods, and results
A total of 149 patients aged 21-76 years were allocated at random to receive intravenous midazolam or diazepam. Treatments were allocated by a prerandomised balanced code not known to either patient or assessor. Because of differences in colour and viscosity of the two solutions they were administered by a physician not participating in endoscopy or assessments.
After sucking a benzocaine tablet the patient received intravenous hyoscine butylbromide 20 mg (Buscopan) followed by diazepam 10 mg or midazolam 7-5 mg as a bolus (with smaller doses for elderly patients) into a large vein in the antecubital fossa. Further increments were given rapidly until the physician judged sedation to be adequate; maximal sedation was not awaited.
Recovery from sedation was monitored subjectively by questionnaire and objectively by a paper and pencil task (Trieger test),' which assesses psychomotor function, and by critical flicker fusion,' which reflects central integration. The endoscopists rated as "excellent," "good," "fair," or "poor" the following: patient cooperation; overall tolerance of the procedure; ease of examination; muscle relaxation; and control of gag reflex, laryngospasm and retching, vomiting, and salivation. Before discharge at two hours and again at 24 hours the patients completed a questionnaire on recall and pleasantness or unpleasantness of the procedure. The veins were checked again after one week.
Frequency tables were tested using either Fisher's exact or the x2 (with Yates's correction) two tailed test.
The mean dose of midazolam was 10-3 mg (range 5-15 mg) and of diazepam 12-5 mg (range 10-20 mg). The speed of injection and rapidity of onset of sedation were similar in both groups; the mean times from injection to the start of endoscopy were 1 9 (SD 1-5) minutes and 1-7 (SD 1-0) minutes for midazolam and diazepam respectively. The mean times for endoscopy were also similar, three quarters of the examinations being done in less than two minutes.
The endoscopists rated both drugs as being equally highly satisfactory, on average "excellent" in 55% and "good" in 27% of cases. In contrast, the patients generally gave significantly better ratings to midazolam (table) . Both the Trieger test and critical flicker fusion showed significantly more impairment at one hour in patients given midazolam but the speed of recovery thereafter was quicker, so that at two hours the results were similar and almost back to pretreatment values. Midazolam induced significantly more amnesia than diazepam; this correlated with better patient acceptability.
Pain on injection and tenderness, redness, and induration at the injection site occurred in 4% and 17% of patients after midazolam and diazepam respectively (difference not significant).
Comment
Intravenous midazolam was at least as effective as intravenous diazepam in allowing quick yet safe endoscopy. Furthermore, the patients graded the sedation with midazolam more highly and the amnesia superior compared with diazepam, though the study was not designed to allow direct patient preference. Venous complications were substantially fewer after midazolam. There were no adverse reactions. The rapid recovery and safety features allowed us to use Patients were not admitted to hospital from the antenatal clinic unless two separate readings taken at the clinic showed the diastolic blood pressure to be greater than 100 mm H-g. Any patient with a diastolic blood pressure
